Precision System Science Co., Ltd.

Precision System Science Co., Ltd.

PCNEF
Precision System Science Co., Ltd.US flagOther OTC
2.28
USD
- -
- -
62.00MMarket Cap
Precision System Science Co., Ltd.
PCNEF
(Other OTC)

Recent

price

2.28

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
443.8
649.62
172.19
192.87
220.76
214.87
281.8
220.64
183.6
157.85
179.98
195.51
341.7
269.03
191.03
144.04
143.99
Revenue per Share
8.59
63.37
-20.09
-10.36
55.58
33.53
-11.79
-78.29
-26.5
-19.84
5.35
-4.41
29.25
1.64
-47.93
-40.59
-40.57
Basic EPS, GAAP
35.54
39.83
-31.11
-25.26
-9.77
-78.98
-86.04
-9.82
-51.2
-6.4
-20.54
-9.71
-76.9
-49.94
-5.86
-4.73
- -
Free Cash Flow per Basic Share
- -
- -
7.35
0.03
0.01
11.29
7.44
0.02
0.01
- -
- -
- -
- -
5.01
- -
- -
- -
Dividend per Share
-11.22
352.71
140.12
129.76
185.34
207.37
188.08
128.98
-43.99
87.68
100.23
98.7
149.8
194.52
146.61
-58.41
-58.39
Book Value per Share
297.97
387.89
155.49
142.07
448.49
233.15
218.22
169.78
178.93
142.62
163.22
165.77
235.81
220.47
176.51
144.92
144.87
Tangible Book Value per Share
9
9
18
18
18
18
18
20
21
23
24
26
27
28
28
28
28
Basic Weighted Avg Shares
3,802
5,638
3,143
3,520
4,029
3,922
5,143
4,458
3,847
3,641
4,381
5,067
9,299
7,434
5,278
3,980
3,980
Sales/Revenue/Turnover
6.79
12.75
-13.75
-3.87
-3.13
-22.73
-6.23
-16.55
-11.45
-10.59
3.74
-1.63
9.63
2.05
-21.08
-24.03
-24.03
Operating Margin (%)
167
107
136
124
182
224
292
292
104
83
86
122
374
535
641
409
- -
Depreciation Expense
74
550
-367
-189
1,014
612
-215
-1,582
-555
-458
130
-114
796
45
-1,324
-1,121
-1,121
Net Income, GAAP
67.25
18.02
- -
- -
- -
40.03
- -
- -
- -
- -
6.4
- -
- -
72.92
- -
- -
7.43
Effective Tax Rate (%)
1.94
9.76
-11.67
-5.37
25.17
15.6
-4.18
-35.48
-14.43
-12.57
2.97
-2.26
8.56
0.61
-25.09
-28.18
-28.18
Profit Margin (%)
2,532
3,087
2,594
2,729
4,401
3,403
3,320
3,386
3,650
2,977
3,413
3,488
5,226
4,772
3,865
2,651
2,651
Working Capital
751
643
821
1,093
809
666
736
618
628
386
233
326
1,285
2,672
2,522
290
290
LT Debt
2,559
3,370
2,862
2,614
8,241
4,325
4,035
3,432
3,751
3,291
3,977
4,321
6,579
6,512
5,222
4,143
4,143
Total Equity
2.3
14.13
- -
- -
- -
-6.58
- -
- -
- -
- -
3.23
- -
- -
0.39
- -
- -
- -
Return on Invested Capital (%)
8.48
22.8
- -
- -
- -
-8.19
- -
- -
- -
- -
4.2
- -
- -
0.65
- -
- -
-24.83
Return on Capital (%)
- -
- -
-13.05
-7.68
35.28
17.08
-5.96
-52.4
- -
- -
5.84
-4.57
24
0.96
-28.1
- -
-28.11
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'24
Mar'24
Jun'24
ST Debt
1,339
1,084
1,077
LT Borrowings
2,255
353
290
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
28
28
Market Capitalization
- -
- -
3,337

Working Capital

FRC

in mil. unless spec.
Dec'24
Mar'24
Jun'24
Total Current Assets
5,054
4,829
4,610
Cash, Cash Equivalents & STI
2,042
2,050
1,915
Accounts Receivable, Net
816
650
650
Inventories
1,930
1,815
1,695
Total Current Liabilities
1,914
1,815
1,959
Payables & Accruals
- -
- -
- -
ST Debt
1,339
1,084
1,077
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.57%
3.88%
-20.67%
Free Cash Flow
105.45%
108%
-19.27%
Net Income, GAAP
-382.59%
-822.97%
-15.31%
Sales/Revenue/Turnover
4.46%
5.1%
-24.6%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
1,526
1,597
1,084
1,070
5,278
2024
1,072
940
929
1,039
3,980
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-10.43
- -
- -
- -
-47.93
2024
-7.88
- -
- -
- -
-40.59
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Business
Precision System Science Co., Ltd. develops, manufactures, and distributes automated systems and instruments primarily for genetic and protein analysis as well as in vitro diagnostics. Its core products include nucleic acid extraction systems such as the magLEAD series (including magLEAD 5bL and discontinued magLEAD 12gC), and the fully automated molecular diagnostics geneLEAD series including geneLEAD XII plus and geneLEAD VIII, which cover processes from nucleic acid extraction to real-time PCR analysis. The company also supplies plastic consumables, reagents for nucleic acid extraction and biochemical testing, and research-focused instruments such as the LecChip series. Precision System Science utilizes proprietary Magtration technology, a recognized standard for automated nucleic acid extraction, integrated in its automated real-time PCR systems. The company operates primarily in Japan and serves global markets with its CE-IVD certified products. Founded in 2002 and headquartered in Chiba, Japan, Precision System Science continues to advance solutions for gene and protein analysis. Recent major developments include the company’s strategic 5-year OEM product supply agreement with ELITechGroup initiated in 2024, enhancing its molecular diagnostics market presence. In 2024, Precision System Science divested Universal Bio Research Co., Ltd. through a sale valued at approximately ¥60 million, signaling a refinement of its business portfolio. It also launched joint sales efforts for its geneLEAD XXIV and magLEAD 4gC and 12gC LiNK systems to expand product reach. The company maintains close collaborations, including a distribution agreement with DiagCor Life Science Ltd., and continues to emphasize growth in automated molecular testing platforms and sample-to-result instrumentation. These actions reflect Precision System Science's ongoing commitment to advancing automated gene and protein analytical solutions in the healthcare and life sciences sectors.

Company News

APIChat
  • Health stocks jump as WHO declares mpox global health emergency